Elicio Therapeutics, Inc (ELTX)

Elicio Therapeutics' stock (ELTX) has fluctuated between $4.60 and $14.93 over the past 52 weeks. In March 2026, the stock price experienced daily and weekly fluctuations, and the company reported inducement grants of stock options to a new employee. H.C. Wainwright raised the firm's price target on ELTX to $17 from $13, maintaining a Buy rating. The company reported its full-year 2025 financial results and provided corporate updates, including the anticipation of the event-driven primary Disease-Free Survival (DFS) analysis for the Phase 2 AMPLIFY-7P study in the first half of 2026, and launched a new $100 million At-The-Market (ATM) program. In February 2026, Elicio Therapeutics was scheduled to present at the TD Cowen 46th Annual Health Care Conference. In November 2025, the company reported third-quarter 2025 financial results and corporate updates, noting that the event-driven primary DFS analysis for the Phase 2 AMPLIFY-7P trial was now expected in 1H 2026. In December 2025, Elicio reported evidence of antigen spreading beyond mKRAS to patient-specific neoantigens in the Phase 2 AMPLIFY-7P trial.

Based on six years of historical data, May has been the strongest month for ELTX, with an average return of 23.27%, while October tends to be the weakest month, averaging a -19.21% return. The stock has an average annual return of -1.66% with a monthly win rate of 37.2%, and its seasonal pattern consistency score is considered "Poor" at 48.2.

Elicio Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing novel cancer immunotherapies using its proprietary Amphiphile (AMP) platform to deliver immunotherapeutics directly to the lymph nodes. The company's major product candidates include ELI-002, a multivalent lymph node-targeted AMP peptide vaccine in Phase II clinical trials for KRAS-driven cancers; ELI-004, an AMP-modified CpG adjuvant; ELI-007, an AMP-peptide vaccine in preclinical studies for mutant BRAF-driven cancers; and ELI-008, a multivalent AMP-peptide vaccine in preclinical studies for TP53 expressing cancers. The company previously developed ELI-005, ELI-011, and ELI-012.

Elicio Therapeutics, Inc. is headquartered in Boston, Massachusetts, and is incorporated in Delaware. The company's primary operations are focused on research and development, with clinical trials being conducted.

Elicio Therapeutics generally holds a positive brand reputation within the analyst community, particularly concerning its scientific advancements and clinical trial progress. The company has a consensus rating of "Moderate Buy" from analysts. Positive clinical updates, such as robust T-cell responses and antigen spreading observed in the AMPLIFY-7P trial, contribute to a favorable perception.

Elicio Therapeutics' ownership is a mix of institutional, retail, and individual investors. Institutional investors hold approximately 35.03% of the stock, with major shareholders including Knoll Capital Management, LLC, and Vanguard Group Inc. Retail investors hold a substantial stake, around 52% as of November 2025. Yekaterina Chudnovsky is a significant individual shareholder, owning 31% of shares outstanding. Insiders own approximately 31.69% to 33% of the company's stock.